US 12,441,793 B2
CD33 antibodies and methods of using the same to treat cancer
Nai-Kong V. Cheung, New York, NY (US); Sayed Shahabuddin Hoseini, New York, NY (US); and Mahiuddin Ahmed, New York, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US)
Appl. No. 17/432,265
Filed by MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
PCT Filed Feb. 21, 2020, PCT No. PCT/US2020/019351
§ 371(c)(1), (2) Date Aug. 19, 2021,
PCT Pub. No. WO2020/172621, PCT Pub. Date Aug. 27, 2020.
Claims priority of provisional application 62/809,091, filed on Feb. 22, 2019.
Prior Publication US 2022/0259307 A1, Aug. 18, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 51/10 (2006.01); A61P 25/28 (2006.01); A61P 35/02 (2006.01); C07K 16/44 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 51/1018 (2013.01); A61K 51/1027 (2013.01); A61P 25/28 (2018.01); A61P 35/02 (2018.01); C07K 16/44 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 22 Claims
 
1. An antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein
(a) the VH comprises a VH-CDR1 sequence of GYSFTDYN (SEQ ID NO: 154), a VH-CDR2 sequence of IDPYKGGT (SEQ ID NO: 155), and a VH-CDR3 sequence of AREMITAYYFDY (SEQ ID NO: 156); and
(b) the VL comprises a VL-CDR1 sequence of QDINKY (SEQ ID NO: 157), a VL-CDR2 sequence of YAS (SEQ ID NO: 158), and a VL-CDR3 sequence of LQYDNLLT (SEQ ID NO: 159), optionally wherein
the antibody or antigen binding fragment binds to the IgC2 domain of CD33, or
the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody, or the antigen binding fragment is selected from the group consisting of Fab, F(ab′)2, Fab′, scFv, and Fv
and optionally wherein the bispecific antibody binds to T cells, B-cells, myeloid cells, plasma cells, or mast-cells, or wherein the bispecific antibody or antigen binding fragment binds to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCR gamma/delta, NKp46, KIR, or a small molecule DOTA hapten.